Cellectar Biosciences (CLRB) News Today $4.50 -0.25 (-5.26%) Closing price 04:00 PM EasternExtended Trading$4.50 0.00 (0.00%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer ...October 14 at 4:33 PM | markets.businessinsider.comCellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer ResearchOctober 14 at 8:30 AM | globenewswire.comOppenheimer Remains a Hold on Cellectar Biosciences (CLRB)October 10, 2025 | theglobeandmail.comCellectar Biosciences enters agreements to raise $5.8MOctober 7, 2025 | msn.comCellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ RallyOctober 7, 2025 | msn.comCellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 MillionOctober 7, 2025 | markets.businessinsider.comCellectar Biosciences Secures Approximately $5.8 Million Through Warrant Exercise Agreement with Institutional InvestorsOctober 7, 2025 | quiverquant.comQCellectar says EMA confirms eligibility to file for CMA for iopofosine I 131October 6, 2025 | msn.comCellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment ...October 6, 2025 | finance.yahoo.comCellectar Biosciences Plans Conditional Marketing Authorization Submission for Iopofosine I 131 as Treatment for Refractory Waldenstrom Macroglobulinemia in Europe by Early 2026October 6, 2025 | quiverquant.comQAnalysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $375.00October 6, 2025 | americanbankingnews.comCellectar Biosciences says Iopofosine I 131 well tolerated in case studiesSeptember 30, 2025 | msn.comCellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and ...September 30, 2025 | markets.businessinsider.comCellectar, Evestia entered into agreement for Phase 1b study of CLR 125September 25, 2025 | msn.comCellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)September 24, 2025 | finance.yahoo.comCellectar Biosciences Partners with Evestia Clinical for Phase 1b Study of CLR 125 in Triple-Negative Breast CancerSeptember 24, 2025 | quiverquant.comQCellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225September 11, 2025 | globenewswire.comCellectar Biosciences Progresses in EMA and FDA Pathways for Iopofosine I 131 and Advances CLR 125 for Triple-Negative Breast CancerSeptember 9, 2025 | quiverquant.comQCellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology SummitSeptember 9, 2025 | globenewswire.comCellectar Biosciences, Inc. Announces Participation in Key Cancer Research Conferences and Panel Discussions This SeptemberSeptember 5, 2025 | quiverquant.comQCellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in SeptemberSeptember 5, 2025 | globenewswire.comCellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer ResearchSeptember 3, 2025 | globenewswire.comCellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in ...August 27, 2025 | finance.yahoo.comCellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric CancerAugust 27, 2025 | globenewswire.comCellectar Cuts Q2 Losses and ExpensesAugust 15, 2025 | theglobeandmail.comCellectar Biosciences Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comCellectar Biosciences target adjusted to $18 from $3 at Roth CapitalAugust 15, 2025 | msn.comCellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comCellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 14, 2025 | globenewswire.comA Peek at Cellectar Biosciences's Future EarningsAugust 14, 2025 | benzinga.comCellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025August 7, 2025 | globenewswire.comAll You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to BuyJuly 15, 2025 | msn.comCLRB - Cellectar Biosciences Inc Dividends - MorningstarJuly 4, 2025 | morningstar.comMChad J. Kolean Acquires 5,000 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) StockJuly 4, 2025 | insidertrades.comCellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option - MorningstarJuly 4, 2025 | morningstar.comMCellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering - MorningstarJuly 2, 2025 | morningstar.comMCellectar Biosciences prices $6 million public offeringJuly 2, 2025 | investing.comCellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - NasdaqJuly 2, 2025 | nasdaq.comCellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment OptionJuly 2, 2025 | globenewswire.comCellectar Biosciences Shares Drop After $6M Public Offering PricesJuly 1, 2025 | marketwatch.comCellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 MillionJuly 1, 2025 | quiverquant.comQCellectar Biosciences Announces Pricing of $6 Million Underwritten Public OfferingJuly 1, 2025 | globenewswire.comCellectar Biosciences enacts one-for-thirty reverse stock split on NasdaqJune 27, 2025 | uk.investing.comCellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply AgreementJune 26, 2025 | theglobeandmail.comCellectar Biosciences, Inc. (CLRB) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comCellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply AgreementJune 26, 2025 | globenewswire.comCellectar Biosciences (NASDAQ:CLRB) Shares Gap Down - Time to Sell?June 24, 2025 | marketbeat.comCellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)June 24, 2025 | globenewswire.comCellectar Biosciences, Inc.: Cellectar Biosciences Announces One-for-Thirty Reverse Stock SplitJune 19, 2025 | finanznachrichten.deCellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025June 18, 2025 | quiverquant.comQ Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLRB Media Mentions By Week CLRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLRB News Sentiment▼0.150.68▲Average Medical News Sentiment CLRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLRB Articles This Week▼22▲CLRB Articles Average Week Get the Latest News and Ratings for CLRB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cellectar Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ALGS News ANL News ACRV News TLPH News HYPD News BRNS News QNTM News CELU News SKYE News OTLK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLRB) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
